OrthoPediatrics Corp. (NASDAQ:KIDS) Insider Gregory A. Odle Sells 5,359 Shares

OrthoPediatrics Corp. (NASDAQ:KIDS) insider Gregory A. Odle sold 5,359 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total value of $133,224.74. Following the sale, the insider now directly owns 148,788 shares in the company, valued at approximately $3,698,869.68. This represents a 3.48 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

OrthoPediatrics Stock Down 1.1 %

Shares of OrthoPediatrics stock opened at $25.15 on Thursday. The business’s 50 day simple moving average is $24.79 and its 200 day simple moving average is $25.53. OrthoPediatrics Corp. has a 52-week low of $21.02 and a 52-week high of $35.99. The firm has a market cap of $610.82 million, a PE ratio of -20.45 and a beta of 1.22. The company has a debt-to-equity ratio of 0.19, a quick ratio of 3.68 and a current ratio of 7.17.

OrthoPediatrics (NASDAQ:KIDS) last announced its earnings results on Tuesday, March 4th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. The business had revenue of $52.67 million for the quarter, compared to analyst estimates of $51.16 million. During the same quarter last year, the firm earned ($0.23) EPS. On average, analysts predict that OrthoPediatrics Corp. will post -0.93 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Truist Financial dropped their price target on OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating on the stock in a research report on Wednesday, December 18th. Stifel Nicolaus dropped their price target on OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, March 5th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $42.00 price target on shares of OrthoPediatrics in a research report on Wednesday, March 5th.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP increased its position in shares of OrthoPediatrics by 16.2% during the 3rd quarter. Wellington Management Group LLP now owns 883,221 shares of the company’s stock worth $23,944,000 after purchasing an additional 122,846 shares during the last quarter. Barclays PLC increased its position in shares of OrthoPediatrics by 319.3% during the 3rd quarter. Barclays PLC now owns 25,298 shares of the company’s stock worth $686,000 after purchasing an additional 19,264 shares during the last quarter. Geode Capital Management LLC increased its position in shares of OrthoPediatrics by 2.1% during the 3rd quarter. Geode Capital Management LLC now owns 391,492 shares of the company’s stock worth $10,615,000 after purchasing an additional 7,972 shares during the last quarter. Mutual of America Capital Management LLC increased its position in shares of OrthoPediatrics by 195.1% during the 3rd quarter. Mutual of America Capital Management LLC now owns 107,609 shares of the company’s stock worth $2,917,000 after purchasing an additional 71,146 shares during the last quarter. Finally, Centiva Capital LP acquired a new position in shares of OrthoPediatrics during the 3rd quarter worth approximately $319,000. Institutional investors and hedge funds own 69.05% of the company’s stock.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.